Conditions: Prostate Cancer
Keywords: nexrutine prostate cancer
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 21
Healthy volunteers: no

Brief summary:
The purpose of the study is to (1) to determine the rate of PSA decline (the number declining). Tissue will be obtained for ancillary studies and (2) to determine the number of patients with a PSA decline to \<1.0 ng/ml at 3 months in patients receiving Nexrutine® with standard radiation therapy. The Secondary Objective is to confirm the tolerability of this regimen. The Third Objective (Ancillary studies) is To evaluate the molecular response of Nexrutine®. Molecular response is defined as changes in the molecular pathways.

Detailed description:

Arms:
arm 1: Surgery Group: Nexrutine 500mg by mouth, three times per day, given prior to surgery. arm 2: Radiation Group: Nexrutine 500mg by mouth, three times per day, given prior to and during radiation treatment.

Interventions: intervention 1: Nexrutine
Intervention descriptions: intervention 1: Nexrutine 500mg by mouth, three times per day, given prior to surgery or prior to and during radiation treatment.

Protocol document: